Montex

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Montex

Property Description
Active Ingredient Montelukast Sodium
Form Oral (Tablet, Chewable Tablet, Granules)
Pharmacological Class Leukotriene Receptor Antagonist (LTRA)
Common Use Long-term control of airway inflammation
Origin Synthetic

The Chemical Identity and Pharmacological Class of Montex

Montex is a synthetic, single-ingredient prescription medication defined by its active compound, Montelukast Sodium (INN). As a drug entity, it is clinically recognized for its high selectivity and oral efficacy. Montex belongs to the specialized class of Leukotriene Receptor Antagonists (LTRA), a therapeutic category designated for modifying the inflammatory response. This classification positions it uniquely among respiratory treatments, as it focuses on inhibiting specific chemical messengers rather than acting as a direct bronchodilator.

What Type of Preparation is Montelukast?

Montelukast is an orally administered medication, ensuring systemic distribution throughout the body after absorption from the digestive tract. It is available in three primary dosage forms to accommodate various patient groups: the standard film-coated tablet, a chewable tablet, and a formulation of oral granules. The availability of the chewable tablet and granules distinguishes it, offering ease of administration for adolescents and children. Montelukast is primarily metabolized by the liver, solidifying its systemic route of action within the body.

General Purpose: Managing Airway Inflammation

The fundamental purpose of Montex is to function as a controller medicine by stabilizing the airways and mitigating chronic inflammation. It achieves this by selectively blocking the activity of cysteinyl leukotrienes—powerful inflammatory messengers—that otherwise trigger undesirable airway effects. The agent is typically used in a scenario requiring prophylaxis and consistent long-term management, thereby helping to reduce three core features of airway inflammation: the tightening of smooth muscles (bronchoconstriction), mucus secretion, and the swelling of the lining, providing continuous therapeutic support for stable breathing.

What side effects are possible with Montex?

Official Adverse Reactions and Safety Profile for Montex

The safety profile for Montex is derived strictly from governmental regulatory documents, which formally classify and communicate the medicine's potential risks.

Serious Safety Restrictions

  • Boxed Warning: The regulatory labeling for Montex includes a Boxed Warning—the strongest safety measure—concerning the risk of serious mental health side effects. These have included, but are not limited to, changes in behavior and mood, depression, agitation, and suicidal thoughts and actions.
  • Use Restriction: Due to the risk of these serious events, regulatory authorities advise that Montex be reserved for treating allergic rhinitis only in patients who are inadequately managed by, or cannot tolerate, alternative therapies.

Classified Adverse Reactions

Classification Common Examples (by System-Organ Class)
Very Common (ge 1/10) Upper respiratory infection, fever.
Common (ge 1/100 to <1/10) Headache, abdominal pain, nausea, elevated liver enzymes.

Clinically Significant Adverse Events

Side effects have been reported across several system-organ classes, with Psychiatric Disorders being a major focus of regulatory concern. These include sleep disturbances (such as nightmares or insomnia), anxiety, hallucinations, and aggressive behavior. Other serious, though rare, reactions documented in the regulatory label include hypersensitivity reactions (e.g., anaphylaxis, angioedema) and systemic conditions like Eosinophilic granulomatosis with polyangiitis (Churg-Strauss Syndrome).

Population-Specific Notes

The official safety information notes that certain neuropsychiatric events, such as aggression and nightmares, are reported in pediatric patients (children). Some changes in behavior or mood have been reported to occur during treatment and, in many cases, to resolve after stopping the medicine.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents describe the profile of an overdose with Montex (montelukast) based on reports from acute exposures involving adults and children, with some documented doses reaching up to 1000 mg.

Documented Overdose Signs and Symptoms

Symptoms reported following an acute overdose generally align with the drug's known adverse effect profile. These signs and symptoms may affect the gastrointestinal and central nervous systems, including:

  • Abdominal pain
  • Vomiting
  • Thirst
  • Headache
  • Somnolence (drowsiness)
  • Psychomotor hyperactivity and agitation

Emergency Response

Immediate medical help should be sought if an overdose is suspected. Contact a healthcare provider or a poison control center right away.

Regulatory information indicates that there is no specific antidote or defined treatment for a Montex overdose. Management is therefore symptomatic and supportive, meaning it focuses on treating the specific symptoms that develop and providing necessary care to support vital functions. It is not known whether the drug can be removed from the body using dialysis.

Therapeutic Uses of Montex

What Montex Treats: Main Uses and Benefits

Montex (Montelukast) is commonly used as a controller medication for chronic or recurrent asthma in both adults and pediatric patients. This medication is used to help address the symptoms associated with chronic inflammatory processes that contribute to airway distress. The primary benefit is supporting functional stability for the airways, which contributes to easing the overall symptom load and may assist with managing disruptive night-time symptoms.


Its key therapeutic applications are in managing long-term asthma control, supporting the management of exercise-induced breathing difficulty, and providing supportive relief for allergic rhinitis symptoms.

This medication is commonly applied in conditions marked by heightened symptoms associated with seasonal or perennial allergic rhinitis. It is relevant for easing symptom clusters that may become disruptive, such as nasal congestion, sneezing, and rhinorrhea. This supportive relief helps patients cope more steadily with symptom fluctuations and assists with maintaining functional stability during symptomatic phases.


Quick Fact: Management for Recurrent Breathing Symptoms

Eligibility and Restrictions for Use

Official Eligibility and Contraindications for Montex

Montex (Montelukast Sodium) use is governed by official population rules specified in regulatory documentation. Eligibility is primarily determined by age, the specific condition being treated, and the absence of a known hypersensitivity.

Contraindicated Population
Patients with known Hypersensitivity to Montelukast Sodium or any component of the formulation.

Montex is also not indicated for the treatment of an acute asthma attack or status asthmaticus.


Age-Related Eligibility and Limitations

Official prescribing information establishes minimum age requirements that vary by indication:

  • For Asthma: Use is approved for patients 12 months of age and older. Use in patients younger than 12 months is not established.
  • For Exercise-Induced Bronchoconstriction (EIB): Use is approved for patients 6 years of age and older. Use in younger children is not established.
  • For Allergic Rhinitis: Approval for seasonal allergic rhinitis begins at 2 years of age, while approval for perennial allergic rhinitis begins at 6 months of age.

Conditional Use Status

  • Pregnancy and Lactation: Use during pregnancy and while breastfeeding is conditional. A healthcare provider must evaluate the potential benefits against any potential risks before prescribing.
  • Hepatic Status: No dosage adjustment is required for patients with mild-to-moderate liver impairment. However, use in patients with severe hepatic impairment has not been formally evaluated.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The pharmacokinetics of Montex (montelukast) are primarily influenced by medicines that affect certain liver enzymes, but its use is generally safe with most common treatments for asthma and allergy.

Documented Interaction Mechanisms and Medicinal Products

  • CYP Enzyme Inducers: Co-administration with potent inducers of cytochrome P450 enzymes (specifically CYP 3A4, 2C8, and 2C9) can decrease the systemic exposure and effectiveness of montelukast. Explicitly listed examples include phenytoin, phenobarbital, and rifampicin. Clinical monitoring is advised when these are co-administered.
  • CYP 2C8 Inhibitors: Drugs that potently inhibit CYP 2C8, such as gemfibrozil, may significantly increase the systemic exposure of montelukast (e.g., up to 4.4-fold). Although no routine dose adjustment is specified, physicians should be aware of the potential for increased adverse reactions.
  • Non-Interacting Medications: Montelukast did not show clinically important effects on the pharmacokinetics of many common agents, including theophylline, prednisone, prednisolone, oral contraceptives, digoxin, and warfarin.

Interaction-Related Constraints

  • Corticosteroids: Montelukast must not be abruptly substituted for inhaled or oral corticosteroids. Reduction in corticosteroid dose should be gradual and under medical supervision, due to the rare risk of systemic eosinophilia and vasculitis (Churg-Strauss syndrome).
  • Aspirin Sensitivity: Patients with known aspirin sensitivity must continue to avoid aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) while taking montelukast. Montelukast does not modify the bronchoconstrictor response to these agents in aspirin-sensitive asthmatics.

Mechanism of Action

How Montex Works

The action of Montelukast is defined by its targeted intervention in the body's leukotriene signaling pathway, focusing exclusively on pharmacodynamic mechanisms to alter signaling dynamics in the airways.


Targeting the Cysteinyl Leukotriene 1 Receptor

Montex works by selective competitive antagonism at the Cysteinyl Leukotriene 1 ( CysLT1) Receptor, preventing the binding of pro-inflammatory Cysteinyl Leukotrienes ( LTC4, D4, E4). This molecular blockade inhibits the initiating signal that triggers cellular and systemic consequences.


Modulating Airway Smooth Muscle and Edema

By interrupting the leukotriene-driven signaling cascade, the mechanism inhibits the intracellular processes required for bronchial smooth muscle contraction and vascular leakage (edema). This action affects the smooth muscle tone and decreases leukotriene-mediated fluid accumulation in the airway lining.


Dampening the Inflammatory Cell Response

The drug engages mechanisms that regulate the leukotriene-mediated recruitment and activity of inflammatory cells like eosinophils and mast cells in the respiratory tissues. This modification of the local cellular environment alters cellular activity within the airways.

Dosage and Administration Information

Montex (Montelukast) is used as a maintenance controller medicine and is administered orally on a once-daily schedule. This systemic administration is the only approved route. For most patients receiving Montex for long-term respiratory control, the standard regimen involves taking the prescribed dose once daily in the evening to maintain consistent therapeutic levels. When used only for allergic rhinitis, the daily dose may be taken in the morning or evening. The medication may be taken without regard to food, although the chewable forms require thorough chewing before swallowing.

Standard Administration by Age

The dose is based on age, with no adjustments required for older adults or individuals with mild-to-moderate hepatic or renal impairment. The dosage is uniform for all approved uses within the relevant age groups:

Age Group Standard Daily Dose
Age 15+ years 10 mg
6–14 years 5 mg
2–5 years 4 mg

For the prevention of exercise-induced breathing difficulty, Montex is administered as a single dose taken at least two hours before the activity. This single-dose use is subject to the strict constraint that a patient already on a daily maintenance regimen must not take an additional dose for this purpose within the same 24-hour period.

The oral granules formulation must be handled carefully: the contents must be administered immediately upon opening the packet—either directly or mixed with approved soft foods (like applesauce or rice) or liquids (formula/breast milk)—and must be consumed within 15 minutes of mixing.

Recent Clinical Evidence

Research evidence / Overview of Studies for Montex (Montelukast)

This section provides an overview of the official research that describes the clinical evaluation of Montex, focusing on the types of studies conducted and the patterns of outcomes observed, as reported in authoritative scientific sources.

Evidence for Use in Chronic Asthma Management

Research has extensively examined Montex in the context of long-term asthma management research. The primary source of knowledge comes from Randomized Controlled Trials (RCTs), where the medicine was evaluated in diverse populations, including both adults and pediatric patients as young as 12 months. Studies explored outcomes related to physical discomfort and systemic or functional imbalance, such as changes in lung function measurements and patient-reported outcomes describing perceived discomfort, including day-time and night-time symptom scores. Researchers also monitored the frequency of episodes where symptoms become more noticeable, such as asthma exacerbations.

Evidence for Prevention of Exercise-Induced Bronchoconstriction (EIB)

Montex was evaluated in research exploring conditions characterized by episodic or acute changes that occur after physical activity. The evidence base consists of controlled challenge studies, which are specialized RCTs where participants are observed after a standardized period of exercise. This research primarily examined outcomes monitoring physiological strain or stress, such as the degree of post-exercise reduction in lung function in both adults and children (aged 6 years and older). Less information is available on studies examining its administration after the onset of breathing difficulties.

Evidence for Use in Allergic Rhinitis (Seasonal and Perennial)

The medicine was evaluated in studies relevant in trials assessing short-term or episodic symptom patterns related to allergic rhinitis, a condition marked by functional limitations such as nasal congestion. The evidence base includes short-term RCTs that researched the medicine for use in both seasonal (SAR) and perennial (PAR) allergies. The research provides context for outcomes observed, particularly in patients managing co-existing asthma and allergic rhinitis.

Understanding Research Gaps and Uncertainties

Research provides context but not individual predictions, and findings highlight what is known — and what is still uncertain. The scientific literature indicates several areas where data are still emerging or where certainty remains low. Findings were observed in some studies indicating that individual response to the medicine can vary. There is a significant reliance on observational data to characterize the long-term outcomes, and comparative evidence is lacking for some scenarios relative to established therapies. Data for certain groups, particularly those with specific or complicated comorbidities, remain insufficient to draw broad conclusions.

Key Studies & References

  1. Asthma and allergy guidance: Summary of evidence for leukotriene receptor antagonists

Frequently Asked Questions (FAQ)

Common questions about Montex (FAQ)

Q: How quickly does Montex start working for allergy symptoms?

A: Studies on Montex show that the active ingredient is rapidly absorbed into the body after it is taken orally. It typically reaches its maximum concentration in the bloodstream within two to four hours. While the active ingredient is absorbed relatively quickly, the full therapeutic effect, particularly for chronic conditions, may not be noticed immediately.

Q: What is the typical duration of treatment with Montex?

A: Montex is officially indicated for the chronic and long-term treatment of conditions like asthma and perennial allergic rhinitis. It is designed to be a controller medicine that provides continuous support. As a controller medicine, Montex is often used for daily, long-term management as determined by a healthcare provider.

Q: Do people take Montex every day, or just when they have symptoms?

A: Official regulatory information states that Montex is intended to be taken once daily and should be maintained regularly. The medication is intended for continuous use, even when a patient is feeling well and does not have current symptoms. This medication is not designed to treat an acute, sudden asthma attack.

Q: What happens if you miss a dose of Montex?

A: Regulatory information states that if a dose is missed, the patient should take the next scheduled dose at the regular time. It is advised that a patient does not take two doses at the same time to compensate for a missed dose.

Q: Can Montex cause weird dreams or sleep disturbances?

A: Yes, regulatory documents list sleep disturbances as a known adverse reaction associated with Montex use. This includes abnormal dreams (such as nightmares) and difficulty sleeping (insomnia). These effects are categorized as neuropsychiatric events, and regulatory documents note that patients should be monitored for such changes.

Q: Does Montex make you feel drowsy or tired?

A: Official product information notes that somnolence, which is a state of sleepiness or drowsiness, has been reported as an adverse reaction. Fatigue or general tiredness has also been reported in patients taking Montex. Because these effects have been reported, patients should be mindful of how the medication may affect them when performing tasks that require concentration.

Q: Is dry mouth a common side effect of Montex?

A: Dry mouth has been reported as an adverse reaction in patients. However, according to the official product information derived from clinical trials, dry mouth is not listed among the most commonly occurring side effects.

Q: Are there any long-term side effects associated with Montex use?

A: Official product labeling includes a Boxed Warning regarding the risk of serious mental health side effects, which can occur during treatment. Due to the serious nature of these effects, the official labeling includes a strong recommendation that patients be monitored for changes in mood or behavior while taking Montex.

Q: Can Montex interact with over-the-counter pain relievers?

A: The official label specifically cautions patients who are sensitive to aspirin. These individuals must continue to avoid aspirin and other related non-steroidal anti-inflammatory drugs (NSAIDs) even while taking Montex. For other common, non-aspirin pain relievers, it is best to discuss co-administration with a healthcare provider.

Q: Is it safe to drink coffee while taking Montex?

A: Studies on drug interactions show that Montex does not cause clinically important changes to the way the body processes theophylline, a compound related to caffeine. Based on official interaction studies, there is generally no specific restriction regarding coffee or caffeine consumption. However, all patients should discuss their diet with a healthcare provider.

Q: Does Montex interact with herbal supplements like St. John's Wort?

A: Regulatory information indicates that potent inducers of certain liver enzymes, such as CYP 3A4, can decrease the amount of Montex in the body, potentially reducing its effectiveness. Patients are generally advised to disclose all supplements they are taking to their healthcare provider to avoid potential interactions.

Q: Can Montex be used during pregnancy for allergy relief?

A: The use of Montex during pregnancy is conditional. Official information states that the medication should only be used if the expected benefit is determined to outweigh the potential risk to the fetus. Official information states that human data are currently insufficient to definitively inform the level of drug-associated risk.

Q: Is Montex safe for breastfeeding mothers?

A: It is currently unknown whether the active ingredient in Montex passes into human breast milk. Since it is unknown if the active ingredient passes into human milk, the prescribing decision involves weighing the importance of the drug to the mother versus the risk to the nursing infant.

Q: Can Montex affect mood or cause nervousness?

A: Yes, changes in mood and behavior are recognized as potential adverse reactions. Specifically, official regulatory sources list agitation, anxiousness, and depression among the neuropsychiatric events that have been reported in patients taking Montex.

Q: What are the visible benefits of taking Montex consistently?

A: Clinical studies have measured several functional and symptomatic improvements in patients taking Montex. Observed benefits include increased lung function measurements, and reports of fewer daytime and nighttime asthma symptoms. These types of outcomes are generally associated with improved stability in airway health.

Q: Can Montex cause weight gain?

A: According to the official product information from controlled clinical trials, weight gain is not listed as one of the most common adverse reactions reported by patients.

Q: Is it safe to drive after taking Montex?

A: Dizziness and somnolence (sleepiness) have been reported, which could affect a patient's ability to focus and react. Patients should exercise caution when driving or operating machinery until they understand how Montex affects them.

Q: Is there a risk of Montex causing liver issues?

A: Official safety information indicates that Montex has been associated with reports of liver issues in the postmarketing setting. These reports include cases of different types of liver injury, such as cholestatic hepatitis. If a patient is concerned about liver health, this should be discussed with a healthcare provider.

Q: Can Montex help with nasal congestion specifically?

A: Montex is formally indicated for the relief of symptoms associated with seasonal and perennial allergic rhinitis, which includes addressing nasal congestion. However, it is important to note that nasal congestion was also reported as a common adverse reaction in clinical trials.

Q: Can I stop taking Montex immediately if my symptoms improve?

A: Montex is intended for chronic, daily control and should be continued as prescribed, even if symptoms have improved. Any decision to stop the medication must be made by a healthcare provider. Furthermore, it is important that Montex is not abruptly substituted for inhaled or oral corticosteroids.

Q: Does Montex affect the ability to concentrate?

A: Official safety information lists disturbances in attention and memory impairment as specific neuropsychiatric adverse reactions reported in patients taking Montex. Monitoring for changes in concentration or cognitive function is advised.

Q: Can Montex help with seasonal allergies?

A: Yes, Montex is formally indicated and approved by regulatory bodies for the relief of symptoms associated with seasonal allergic rhinitis (SAR). This indication is supported by evidence from specific clinical trials.

Q: Is it normal to feel a bit dizzy when first starting Montex?

A: Dizziness has been reported as an adverse reaction in clinical trials, although it was not a common occurrence. If a patient experiences dizziness, it is recommended to exercise caution until they understand how the medication affects them.

How should Montex be stored and disposed of?

How to Store and Dispose of Montex

Montex (Montelukast) must be stored and handled according to specific regulatory conditions to maintain its stability.

Storage Requirements

Condition Regulatory Rule
Temperature Store below 30 C or 25 C, depending on the specific product label.
Protection Mandatory to protect from light and moisture.
Packaging Keep the medicine in the original package until ready for use.
Child Safety Must be kept out of the reach and sight of children.

Special Handling and Disposal

Montelukast oral granules, once mixed with food or liquid, must be administered within 15 minutes and must not be stored for later use. If the product is supplied in a bottle pack, it may have a 30-day in-use stability limit after opening.

Any unused or expired product must be disposed of in accordance with local requirements for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Montex found in:

A-Z Index: